The ROYAL MARSDEN NHS Foundation Trust Whole Body Diffusion Weighted MRI in Multiple Myeloma





Christina Messiou Consultant Radiologist, The Royal Marsden Hospital

Traditional view of myeloma



Why ? How ? When ?

New view of myeloma



Inverse grey scale b 900 MIP

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

International Myeloma Working Group JCO 2015

1.Patients with more than one lesion >5mm on MRI should be considered as having symptomatic disease requiring therapy.

2.Whole body MRI: work up of solitary bone plasmacytoma and all patients suspected of having asymptomatic or smouldering multiple myeloma. (spine+pelvis MRI if WB not available)

NICE guideline Published: 10 February 2016 nice.org.uk/guidance/ng35

Imaging for people with suspected myeloma

- 1.3.1 Offer imaging to all people with a plasma cell disorder suspected to be myeloma.
- 1.3.2 Consider whole-body MRI as first-line imaging.
- 1.3.3 Consider whole-body low-dose CT as first-line imaging if whole-body MRI is unsuitable or the person declines it.
- 1.3.4 Only consider skeletal survey as first-line imaging if whole-body MRI and whole-body low-dose CT are unsuitable or the person declines them.
- 1.9.6 For people with myeloma and serological <u>relapse or disease progression</u>, consider one of the following (taking into consideration previous imaging tests):
 - whole-body MRI
 - spinal MRI
 - fluorodeoxyglucose positron emission tomography CT (FDG PET-CT).



















Patient Preference

2D-4 PREDICTORS OF PATIENT PREFERENCES FOR WHOLE BODY MAGNETIC RESONANCE IMAGING COMPARED WITH STANDARD STAGING PATHWAYS FOR THE INVESTIGATION OF SYMPTOMS OF SUSPECTED COLORECTAL OR LUNG CANCER

Anne Miles et al SMDM 2016

107 patients completed questionnaires in the streamline study

Over half of patients undergoing staging scans for suspected colorectal or lung cancer would prefer to have a WB-MRI than CT/ PET-CT

Awareness that WB-MRI does not impart a radiation dose was the item that predicted patient preference for WB-MRI yet only 42% of patients were aware of this attribute.







Why?

How to perform WB-DWI for patients with myeloma

When



Minimum Protocol





Screen 2





Why?
How?

When to perform WB-DWI for patients with myeloma cases not on web version.



iTIMM

Image Guided Theranostics in Multiple Myeloma Prospective Observational Study

Can we detect very small volume residual disease post auto and how does this relate to outcomes?

Response adapted strategies Can we use WB-DWI to escalate treatment and improve outcomes?

Diagnostic WB DWI vs FDG PET/CT vs CT



RMH

A non invasive, sensitive imaging tool designed to provide a package of information tailored to the needs of patients with myeloma

Sensitivity - diffuse and focal disease Mechanical complications Quantitative Acceptable to patients

Providing tools which enable precision and personalized medicine everyday



First line imaging at diagnosis and relapse in UK

Standard of care- trial costs 🗸

Future proofing clinical trials

Aligned with other tumour type developments and technologies ie MR-Linac ? PET/MRI

EDUCATION

Royal College of Radiologists ASM - 2015, 2016 and 2017 Royal Marsden Whole Body MRI course - 2015 BIR Hands on Whole Body MRI in Myeloma Course - 2017 International Cancer Imaging Society - 2017 Hands on Royal Marsden Whole Body MRI course 2017

Acknowledgements



The Patients ! Dr Martin Kaiser Dr Kevin Boyd Sharon Giles, Vonnie Morgan, Prof de Souza Sharon West, David Collins (physics) Prof Gareth Morgan, Prof Faith Davies CRUK and NHS funding to the NIHR Biomedical Research Centre.



National Institute for Health Research

